Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityNon-Current AssetsOther Accumulated ExpensesOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsReceivables - AccuredRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Spyre Therapeutics (SYRE) Accumulated Depreciation (2016 - 2022)

Spyre Therapeutics' Accumulated Depreciation history spans 8 years, with the latest figure at $4.1 million for Q4 2022.

  • For Q4 2022, Accumulated Depreciation rose 47.89% year-over-year to $4.1 million; the TTM value through Dec 2022 reached $4.1 million, up 47.89%, while the annual FY2022 figure was $4.1 million, 47.89% up from the prior year.
  • Accumulated Depreciation reached $4.1 million in Q4 2022 per SYRE's latest filing, up from $2.8 million in the prior quarter.
  • In the past five years, Accumulated Depreciation ranged from a high of $4.1 million in Q4 2022 to a low of $752000.0 in Q4 2018.
  • Average Accumulated Depreciation over 5 years is $2.1 million, with a median of $2.0 million recorded in 2020.
  • Peak YoY movement for Accumulated Depreciation: surged 40.29% in 2019, then surged 87.96% in 2020.
  • A 5-year view of Accumulated Depreciation shows it stood at $752000.0 in 2018, then skyrocketed by 40.29% to $1.1 million in 2019, then soared by 87.96% to $2.0 million in 2020, then soared by 41.3% to $2.8 million in 2021, then surged by 47.89% to $4.1 million in 2022.
  • Per Business Quant, the three most recent readings for SYRE's Accumulated Depreciation are $4.1 million (Q4 2022), $2.8 million (Q4 2021), and $2.0 million (Q4 2020).